Abstract
There is no information on the effect of food or concurrent drug administration on the bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days and most often in combination with other cytotoxic agents. The influence of these factors has been studied in 11 patients, receiving combination cytotoxic therapy for extensive small cell lung carcinoma. Neither food nor concurrent oral or intravenous chemotherapy had a significant effect on the mean plasma concentrations of etoposide, achieved following oral administration. Wide variation in peak plasma concentrations and in area under the concentration time curve (AUC) occurred both between and within patients. It appears unnecessary for patients receiving etoposide (at 100 mg) to fast prior to drug administration. Furthermore, oral etoposide (at 100 mg and at 400 mg) may be given in combination with other cytotoxic agents without compromising its bioavailability.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Harvey, V., Slevin, M., Joel, S. et al. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br J Cancer 52, 363–367 (1985). https://doi.org/10.1038/bjc.1985.202
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.202
This article is cited by
-
Drug interactions in cancer therapy
Nature Reviews Cancer (2006)
-
Pharmacological attempts to improve the bioavailability of oral etoposide
Cancer Chemotherapy and Pharmacology (1995)
-
Etoposide and teniposide
Pharmaceutisch Weekblad Scientific Edition (1988)